Literature DB >> 22569213

Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression.

David Alder1, Martin Braun, Pavel Nikolov, Diana Boehm, Veit Scheble, Roopika Menon, Falko Fend, Glen Kristiansen, Sven Perner, Nicolas Wernert.   

Abstract

ETS gene rearrangements are frequently found in prostate cancer. Several studies have assessed the rearrangement status of the most commonly found ETS rearranged gene ERG, and the less frequent genes, ETV-1, ETV-4, ETV-5, and ELK-4 in primary prostate cancer. However, frequency in metastatic disease is not well investigated. Recently, we have assessed the ERG rearrangement status in both primary and corresponding lymph node metastases and observed that ERG rearrangement in primary prostate cancer transfers into lymph node metastases, suggesting it to be a clonal expansion event during prostate cancer progression. As a continuation, we investigated in this study whether this observation is valid for the less frequent ETS rearranged genes. Using dual-color break-apart fluorescent in situ hybridization assays, we evaluated the status of all less frequent ETS gene rearrangements for the first time on tissue microarrays constructed from a large cohort of 86 patients with prostate cancer and composed of primary and corresponding lymph node metastases, as well as in a second cohort composed of 43 distant metastases. ETV-1, ETV-4, ETV-5, and ELK-4 rearrangements were found in 8 (10%) of 81, 5 (6%) of 85, 1 (1%) of 85, and 2 (2%) of 86 of primary prostate cancer, respectively, and in 6 (8%) of 73, 4 (6%) of 72, 1 (1%) of 75, and 1 (1%) of 78 of corresponding lymph node metastases, respectively. ETV-1 and ETV-5 rearrangements were not found in the distant metastases cases, whereas ETV-4 and ELK-4 rearrangements were found in 1 (4%) of 25 and 1 (4%) of 24, respectively. Our findings suggest that rearrangement of the less frequent ETS genes is a clonal event during prostate cancer progression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569213     DOI: 10.1016/j.humpath.2012.01.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  ETV1 positively regulates transcription of tumor suppressor ARF.

Authors:  Evan Zynda; Mark W Jackson; Partho Bhattacharya; Eugene S Kandel
Journal:  Cancer Biol Ther       Date:  2013-10-23       Impact factor: 4.742

2.  Significantly higher expression levels of androgen receptor are associated with erythroblastosis virus E26 oncogene related gene positive prostate cancer.

Authors:  Jason Rosenbaum; Sally Drew; Wei Huang
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

3.  Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.

Authors:  Diana Mesquita; João D Barros-Silva; Joana Santos; Rolf I Skotheim; Ragnhild A Lothe; Paula Paulo; Manuel R Teixeira
Journal:  Oncotarget       Date:  2015-03-10

Review 4.  Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era.

Authors:  Jiajia Chen; Daqing Zhang; Wenying Yan; Dongrong Yang; Bairong Shen
Journal:  Biomed Res Int       Date:  2013-07-15       Impact factor: 3.411

5.  Five ETS family members, ELF-1, ETV-4, ETV-3L, ETS-1, and ETS-2 upregulate human leukocyte-associated immunoglobulin-like receptor-1 gene basic promoter activity.

Authors:  Qizhi Cao; Shude Yang; Qing Lv; Yan Liu; Li Li; Xiaojie Wu; Guiwu Qu; Xiaoli He; Xiaoshu Zhang; Shuqin Sun; Boqing Li; Jing An; Tao Hu; Jiangnan Xue
Journal:  Aging (Albany NY)       Date:  2018-06-18       Impact factor: 5.682

6.  ceRNA network analysis reveals prognostic markers for glioblastoma.

Authors:  Hao Wang; Heying Zhang; Juan Zeng; Yonggang Tan
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

7.  Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.

Authors:  G Schaefer; J-M Mosquera; R Ramoner; K Park; A Romanel; E Steiner; W Horninger; J Bektic; M Ladurner-Rennau; M A Rubin; F Demichelis; H Klocker
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-02-05       Impact factor: 5.554

8.  ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.

Authors:  David Adler; Jacqueline Ochsenfahrt; Kerstin Fuchs; Glen Kristiansen; Sven Perner; Nicolas Wernert
Journal:  Int J Mol Med       Date:  2012-08-20       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.